期刊
PHARMACEUTICS
卷 14, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics14061214
关键词
CT26/luc colorectal carcinoma; liposomal beta-sitosterol; MMP-9; interleukin-12; interleukin-18; interferon-gamma; bioluminescent imaging
资金
- Cheng Hsien General Hospital National Yang-Ming University Joint Research Program, Taipei, Taiwan [CY10718]
- Ministry of Science and Technology, Taipei, Taiwan [109-2314-B-010-006MY2]
The liposomal encapsulated beta-sitosterol (LS) has been found to have a better inhibition effect on tumor metastasis with lower cytotoxicity compared to beta-sitosterol (SITO). Mice treated with LS showed significantly fewer metastases to the lungs and other tissues/organs, and higher levels of IL-12, IL-18, and IFN-gamma. The underlying mechanism may involve the inhibition of MMP-9 and the elicitation of an antitumoral Th1 immune response.
beta-sitosterol (SITO) has been reported with anticancer effects; however, with poor bioavailability. The current study aimed to investigate whether liposomal encapsulated beta-sitosterol (LS) has a better inhibition effect on tumor metastasis than beta-sitosterol in a CT26/luc lung metastasis mouse model and the possible underlying mechanism. LS was liposomal-encapsulated SITO and was delivered to mice by oral gavage. The cell viability was determined by the MTT assay, and invasiveness of the tumor cells and related protein expression were evaluated with the invasion assay and Western blotting. For therapeutic efficacy evaluation, male BALB/c mice were treated with PBS, SITO, and LS once a day for 7 days prior to intravenous injections of CT26/luc cells; treatments were continued twice a week post-cell inoculation throughout the entire experiment. Tumor growth inhibition was monitored by bioluminescent imaging (BLI). IL-12, IL-18, and IFN-gamma in the intestinal epithelium were determined by ELISA. The results show that LS treatment had a better invasion inhibition with lower cytotoxicity than SITO when the same dose was utilized. Notably, mice treated with LS significantly exhibited fewer metastases to the lungs and other tissues/organs compared with the Control and SITO groups. Additionally, the IL-12, IL-18, and IFN-gamma levels were significantly increased in the LS-treated mice compared with the Control and SITO groups. The underlying mechanism may be through the inhibition of MMP-9 and elicitation of the antitumoral Th1 immune response, such as increasing CD4(+) and CD8(+) T cells, IL-12, IL-18, and IFN-gamma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据